Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far

Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far

Switching patients from a reference to a biosimilar product has become a primary topic of interest, with different approaches being undertaken by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In European countries, substitution of a reference medicine with a bi...

Full description

Bibliographic Details
Main Authors: Anna La Noce, Marcin Ernst
Format: Article
Language:English
Published: European Medical Journal 2018-09-01
Series:European Medical Journal
Subjects:
biosimilar
interchangeability
post-marketing studies
real-world evidence
Online Access:https://www.emjreviews.com/rheumatology/article/switching-from-reference-to-biosimilar-products-an-overview-of-the-european-approach-and-real-world-experience-so-far/

Internet

https://www.emjreviews.com/rheumatology/article/switching-from-reference-to-biosimilar-products-an-overview-of-the-european-approach-and-real-world-experience-so-far/

Similar Items